Translated title of the contribution: Radioactive iodine therapy in Europe - A survey

H. Schicha, K. Scheidhauer

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Treatment with 131I is a well known and widely accepted therapy for benign thyroid disease and thyroid cancer. High dose 131I therapy for ablative reasons in well-differentiated thyroid cancer is done mostly in hospitals with controlled area and adequate equipment for radiation protection. Low-dose therapies, however of hyperthyreoidism, thyroid autonomy and goiter may be done in out-patients in many countries. Limits of radioactivity administered for an ambulant therapy are varying. In Germany, 131I therapy of out-patients is generally not permitted. As many patients are waiting for a therapy but capacity is too low, waiting lists up to several months exist. This leads to a kind of medical tourism into other countries where therapy of out-patients is possible. This is a crucial point with regard to optimal medical care as well to health economics. This paper presents the results of a questionnaire which was sent to the national EANM delegates of all European countries. There is a great variability among these countries which indicates the different views handling of radioactivity and radiation protection. A more detailed questionnaire about regulatory and administrative rules initiated by an EANM task group for risk assessment in nuclear medicine is on the way.

Translated title of the contributionRadioactive iodine therapy in Europe - A survey
Original languageGerman
Pages (from-to)321-324
Number of pages4
Issue number6
StatePublished - 1993
Externally publishedYes


Dive into the research topics of 'Radioactive iodine therapy in Europe - A survey'. Together they form a unique fingerprint.

Cite this